Petros Pharmaceuticals, Inc. (PTPI)

NASDAQ: PTPI · IEX Real-Time Price · USD
1.73
+0.23 (15.33%)
At close: Sep 29, 2023, 4:00 PM
1.65
-0.08 (-4.62%)
After-hours: Sep 29, 2023, 7:15 PM EDT
15.33%
Market Cap 3.66M
Revenue (ttm) 3.85M
Net Income (ttm) -21.98M
Shares Out 2.11M
EPS (ttm) -10.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 54,389
Open 1.51
Previous Close 1.50
Day's Range 1.48 - 1.75
52-Week Range 0.92 - 9.54
Beta 1.98
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2023

About PTPI

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health... [Read more]

Sector Healthcare
Founded 2020
Employees 24
Stock Exchange NASDAQ
Ticker Symbol PTPI
Full Company Profile

Financial Performance

In 2022, PTPI's revenue was $5.99 million, a decrease of -23.29% compared to the previous year's $7.81 million. Losses were -$20.04 million, 123.0% more than in 2021.

Financial Statements

News

Petros Pharmaceuticals to Present at the LD Micro Main Event XVI

NEW YORK, NY / ACCESSWIRE / September 28, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway, announ...

2 days ago - Accesswire

Petros Pharmaceuticals Provides Letter to Shareholders

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provide...

19 days ago - Accesswire

Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces toda...

23 days ago - Accesswire

Petros Pharmaceuticals Announces Capital Raise of $15 Million

Provides Update on Progress Toward Over the Counter (non-prescription) Development of STENDRA NEW YORK, NY / ACCESSWIRE / July 13, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or "the C...

2 months ago - Accesswire

Petros Pharmaceuticals Announces Reverse Stock Split

Common Stock Will Begin Trading on Split-Adjusted Basis on December 1, 2022 NEW YORK, NY / ACCESSWIRE / November 30, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq:PTPI), a le...

10 months ago - Accesswire

Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update

NEW YORK, NY / ACCESSWIRE / November 15, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial r...

11 months ago - Accesswire

New FDA-Approved Labeling for Petros Pharmaceuticals' STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy

Expanded STENDRA Labeling Now Includes Data on a Significant Population of Men Not Previously Included Following Submission of Additional Clinical Trial Data NEW YORK, NY / ACCESSWIRE / October 25, 20...

1 year ago - Accesswire

Petros Pharmaceuticals to Participate in Two October 2022 Conferences

NEW YORK, NY / ACCESSWIRE / October 21, 2022 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Offi...

1 year ago - Accesswire

Internationally Published, Head-to-Head Data From India of Petros Pharmaceuticals' STENDRA(R) (Avanafil) Tablets Reported Improvement in Erectile Function Compared to Sildenafil and Baseline After 12 Weeks of Therapy

Data Published in the "International Journal of Urology" Also Showed Secondary Endpoints, Such as Onset of action in 15 Minutes and Percentage of Patients Reaching Normal Erectile Function According t...

1 year ago - Accesswire

Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022

NEW YORK, NY / ACCESSWIRE / August 15, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial res...

1 year ago - Accesswire

Petros Pharmaceuticals Responds to Fraudulent Press Release

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today confirmed that a press release issued on July 28, 20...

1 year ago - GlobeNewsWire

Petros Pharmaceuticals to be Acquired by Henry Crown and Company for $3.25 per share

Petros Pharmaceuticals to become a privately-owned company operating independently as part of Henry Crown and Company's healthcare platform

1 year ago - GlobeNewsWire

Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew Pinsky

Dr. Drew to Raise Awareness of Petros Pharmaceuticals' Mission in The Men's Health Category and STENDRA® (avanafil) Dr. Drew to Raise Awareness of Petros Pharmaceuticals' Mission in The Men's Health C...

1 year ago - GlobeNewsWire

Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced financial resul...

1 year ago - GlobeNewsWire

Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US

Company Is Developing H-100 as Potentially the First FDA-Approved, Nanoparticle-Based Topical Treatment Designed to Provide Improved and Sustained Local Medication Permeation Against Peyronie's Diseas...

1 year ago - GlobeNewsWire

Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Offic...

1 year ago - GlobeNewsWire

Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology

Sensor Measures Oxygen Levels Within Specific Human Tissue, Potentially Allowing Biosensor Feedback of Erectile Device Therapy Sensor Measures Oxygen Levels Within Specific Human Tissue, Potentially A...

1 year ago - GlobeNewsWire

Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights

NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces financial res...

1 year ago - GlobeNewsWire

Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Offic...

1 year ago - GlobeNewsWire

Petros Pharmaceuticals Partners with Celebrity Physician Dr. Drew to Bring Awareness to Men's Health

NEW YORK, Feb. 1, 2022 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has signed a collaboration agreement wi...

1 year ago - PRNewsWire

5 Short Squeeze Candidates To Watch: Insignia Systems, American Virtual Cloud Top List Again, Reliance Global Rejoins

Potential short squeeze plays gained steam in 2021 with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Other symbols: ENSCRELI
1 year ago - Benzinga

Petros Pharmaceuticals Announces Closing of $7.5 Million Offering

NEW YORK, Dec. 28, 2021 Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced the closing of its previously announced registered direct offe...

1 year ago - PRNewsWire

5 Short Squeeze Candidates To Watch: Biofrontera Rejoins And Tops List, 2 New Names Enter Leaderboard

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile ...

Other symbols: BFRIIINNQLGNRELI
1 year ago - Benzinga

Petros Pharmaceuticals Announces $7.5 Million Offering

NEW YORK, Dec. 22, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that it has entered into definitive agreements...

1 year ago - PRNewsWire

5 Short Squeeze Candidates To Watch: Petros Pharmaceuticals, iSpecimen Top The List Again

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge movie. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile...

Other symbols: ISPCLGVNRELI
1 year ago - Benzinga